Introduction
Regulation of haematopoiesis by a local bone marrow renin-angiotensin system (RAS) has been the subject of investigation since the association of haematological abnormalities with classes of drugs that suppress the actions of angiotensin II (Ang II) was first described. 1 Anaemias in patients treated with angiotensin-converting enzyme (ACE) inhibitors 2 were paralleled in ACE-deficient mice, in which Ang II infusion reversed anaemia without raising blood pressure. 3 Not only are all the components of the RAS detectable in bone marrow and marrow-derived circulating blood cells, but there is also considerable evidence that supports the involvement of Ang II in several haematological processes. [4] [5] [6] [7] The actions of Ang II are primarily mediated through AT 1 -and AT 2receptors, both of which are seven-transmembrane G-protein coupled receptors that share approximately 34% homology. 8, 9 The cell signalling and physiological effects associated with AT 1receptor activation are currently the most thoroughly defined. The necessity of AT 1 -receptors for normal progression of haematopoiesis was demonstrated by the development of panleukopeania and progenitor cell dysfunction in wildtype mice transplanted with AT 1 -receptor-deficient bone marrow. 10 Patients with post-transplant erythrocytosis (PTE) exhibited increased AT 1 -receptor density in erythroid precursors and a positive correlation of AT 1 -receptor expression with haematocrit, 11 supporting a role for AT 1receptor signalling pathways in aberrant haematopoiesis. Stimulatory haematopoietic actions of Ang II were demonstrated in mice with irradiation-and chemotherapy-induced myelosuppression, whereas Ang II-mediated restoration of haematopoiesis was blocked by the AT 1 -receptor antagonist, losartan. 12, 13 More recently, pre-treatment of myeloablated mice with telmisartan, another AT 1 -receptor antagonist, increased survival rate and protected bone marrow haematopoietic stem cells (HSC) from radiotoxicity. 14 The mechanisms accounting for the in vivo actions of Ang II may be due to the direct effects of Ang II on HSC, since blockade of CD34 + cell AT 1receptor-mediated activity resulted in suppression of erythroid and myeloid precursor development. 15, 16 These studies suggest that Ang II directly influences bone marrow dynamics through AT 1receptor stimulation by influencing haematopoietic events as early as HSC entry into the cell cycle. Taken together, the direct in vivo effects of Recently, we reported the first systematic study of the bone marrow RAS in the rat 17 which included detection of all major RAS components at the mRNA and protein level in various haematopoietic cell lineages and the production of Ang II by marrow stromal cells (MSC). Within the marrow microenvironment, HSC and committed haematopoietic precursors interact with the local MSC, which are crucial to normal bone marrow function in that they provide the majority of necessary growth factors for the regulation of haematopoietic cell development. 18, 19 Since human HS-5 MSC express AT 1 -receptor mRNA 15 and we showed that rat MSC express AT 1 -and AT 2receptor mRNA and protein, 17 regulation of MSC function may represent an additional pathway by which Ang II influences haematopoiesis. Arachidonic acid (AA), a biologically active fatty acid released by MSC, modulates differentiation of HSC and erythroid and myeloid precursors through eicosanoid metabolites and the production of haematopoietic regulatory factors, 20, 21 and may also directly alter the function of HSC. 22 Release of AA by AT 1 -and AT 2 -mediated receptorstimulation of a variety of cell types results in altered cell growth and proliferation, 23, 25 suggesting that MSC may also respond to Ang II by increased AA release. Recent reports indicate that Ang II is also involved in the secretion of macrophage colony stimulating factor (MCSF), a growth factor produced by MSC that stimulates proliferation and differentiation of myeloid lineage cells. Serum MCSF was reduced following treatment with the AT 1 -receptor antagonist, CS-866, in cholesterol-fed monkeys 26 and following treatment with the ACE inhibitor, enalapril, in patients with coronary artery disease. 27 The relationship between Ang II and tissue generation of AA and MCSF, the capacity of MSC to produce these haematopoietic regulatory factors, and the expression of Ang II AT 1 -receptors by human MSC, suggests a mechanistic connection for Ang II-mediated haematopoiesis. With this in mind, we investigated whether monkey and human MSC respond to Ang II stimulation by increasing AA release and MCSF secretion.
Methods
All chemicals and reagents used in this study were obtained from Sigma (St. Louis, MO, USA), unless otherwise indicated.
Animal protocols
Cynomolgus monkeys (Macaca fascicularis) of Indonesian origin were anaesthetised with ketamine (20 mg/kg, i.m.), and bone marrow aspirates were acquired from the humerus with 20 gauge Yale spinal needles (Becton Dickinson, Franklin Lakes, NJ, USA) attached to sterile 10 ml syringes containing sodium heparin. Housing, experimen-tal procedures, and environmental enrichment were approved by the Institutional Animal Care and Use Committee and performed in accordance with the standards established by the US Department of Health and Human Resources and US Drug Administration.
Marrow stromal cell cultures
Primary MSC from 10 adult male cynomolgus monkeys (body weight 5.43 ± 0.23 kg) were isolated from 2 mL of humeral bone marrow aspirate, using differential adherence to plastic. 28 Briefly, MSC were cultured in T-75 flasks with α-Modified Essential Medium (Gibco BRL, Grand Island, NY, USA) containing 20% foetal bovine serum (FBS), 4 mmol/L L-glutamine, 0.1 units/mL penicillin, and 0.1 mg/mL streptomycin. Non-adherent cells were removed from MSC cultures after 3 days, and media was refreshed bi-weekly. Cells from passages 2-5 were dissociated using 1 mmol/L ethylene-diamine-tetraacetic acid (EDTA) and analysed by flow cytometry to confirm the absence of haematopoietic cells in monkey MSC cultures. Approximately 1.0 x 10 6 cells were evaluated for expression of haematopoietic lineage markers by incubation with phycoerythrin (PE)-conjugated mouse monoclonal antibodies to human CD34, CD45, CD14 and CD11b (BD-Biosciences, San Jose, CA, USA), as previously described. 29 Antibodies to human antigens were demonstrated to cross-react with cynomolgus monkey antigens by the manufacturer. Appropriate isotype controls were included for each antibody. Human HS-5 MSC (CRL-11882,ATCC, Rockville, MD, USA), were cultured as previously described 30 in Dulbecco's Minimal Essential Medium (Gibco BRL) containing 10% FBS, 1.5 g/L sodium bicarbonate (NaHCO3), 4 mmol/L L-glutamine, 0.1 units/mL penicillin, and 0.1 mg/mL streptomycin. Images were obtained using an Olympus CK40-SLP inverted microscope (Olympus, Melville, NY, USA) at a magnification of 100X with a 6V30W halogen lightsource and a Sony Cybershot 5-megapixel digital camera (Sony, Tokyo, Japan). Photoshop 7.0.1 for Windows (Adobe, San Jose, CA, USA) was used for image processing.
Marrow stromal cell AT 1 -and AT 2 -receptor expression
Cells were harvested at confluence under normal growth conditions for analysis of AT 1 -and AT 2receptor mRNA and protein. The mRNAs for AT 1and AT 2 -receptors were identified by reverse-transcriptase-polymerase chain reaction (RT-PCR) as previously described 17 with the following modifications. Human gene-specific primers:AT 1 -receptor forward-5`-TGCTTTCCATTATGAGTCCC-3`, reverse- cDNA insert (nucleotides -20 to +1486) was used to validate the AT 2 -receptor primers. Amplification products were separated on a 6% polyacrylamide gel and visualised using phosphorimage analysis. Determinations were made from six monkey samples and six sets of HS-5 cell passages. Protein for AT 1 -and AT 2 -receptors was analysed by flow cytometry using a 1:100 dilution of rabbit polyclonal antibodies determined by the manufacturer to cross-react with rat and human AT 1 -and AT 2receptors (Research Diagnostics, Inc., Flanders, NJ, USA) and which we previously showed detect AT 1and AT 2 -receptors in rat MSC. 17 A secondary FITCconjugated anti-rabbit IgG antibody (1:200 dilution) was used as a fluorescent tag; analysis of secondary antibody alone was included as a negative control. A preliminary doseresponse study for 3 H-AA release from HS-5 cells using increasing concentrations of Ang II (10 -10 -10 -5 mol/L) determined that 1.0 µmol/L elicited a submaximal response. This concentration of Ang II was used to stimulate MSC throughout the remainder of the study. As a positive control for 3 H-AA release, MSC were stimulated with phorbol-myristate-acetate (PMA, 1.0 µmol/L), a compound that stimulates release of AA from a variety of cell types. [32] [33] [34] [35] Release of 3 H-AA by MSC into media was quantified using a liquid scintillation counter.
Marrow stromal cell arachidonic acid release
Results are reported as a percentage of the 3 H-AA release by vehicle control-treated samples.
Marrow stromal cell MCSF secretion
Secreted MCSF from MSCs was measured in culture medium using a quantitative sandwich enzyme immunoassay for human MCSF (Quantikine Kit, R&D Systems, Minneapolis, MN, USA) according to the manufacturer's instructions. Because cross-reactivity with cynomolgus monkey antigens was not previously validated for this assay system, only human HS-5 cells were studied for MCSF secretion. Cells were plated (3.0x10 5 cells/well) in growth medium and changed to SF medium after 24 hours. Following an additional 24 hours incubation in SF medium, cells were treated in SF medium for 24 hours under the following conditions: vehicle control, Ang II (1.0 µmol/L),Ang II + losartan (1.0 µmol/L), Ang II + PD 123319 (1.0 µmol/L),Ang II + losartan + PD 123319, or PMA (1.0 µmol/L). Culture medium was collected, centrifuged for 10 min at 5,000 x g to remove debris, and immediately frozen in aliquots at -20°C. The manufacturer reported the range of detection for this assay as 0-2,000 pg/mL, with a minimum detectable concentration estimated at 9.0 pg/mL.
Statistical analysis
Data represent triplicate measures from at least five experiments for each condition and are reported as mean ± SEM. Statistical analysis was performed using the two-tailed Student's paired t-test with significance set at p<0.05 using GraphPad Prism version 3.0 for Windows (GraphPad Software, San Diego, CA, USA).
Results
Primary monkey MSC reached confluence after approximately 10 days and were subcultured and studied at passages 2-5. Subcultured cells, illustrated in Figure 1A , were primarily fibroblastic in appearance, with typical spindle and triangular shapes consistent with previous characterisations of cynomolgus monkey MSC. 28 We analysed cells for haematopoietic markers by flow cytometry to determine whether contaminating haematopoietic These results agree with studies in rat and human MSC showing that early passages contain no detectable CD45+ and low amounts of CD11b + . [36] [37] [38] The HS-5 cell line represents a subset of human MSC that are also fibroblastic but more homogenous in appearance than primary monkey MSC, as illustrated in Figure 1B . Previous analysis of HS-5 cells determined that they were devoid of haematopoietic lineage cells. 21, 30 
AT 1 -and AT 2 -receptor expression in monkey and human HS-5 marrow stromal cells
Characterisation of monkey and HS-5 MSC by RT-PCR demonstrated AT 1 -receptor mRNA in both cell types (Figure 2A) . In contrast, AT 2 -receptor mRNA was not detected in either MSC cell type ( Figure 2B ). Immunodetection of Ang II receptor protein by flow cytometry showed that the percentages of cells expressing AT 1 -receptors cells was greater (p<0.05) than isotype control in both monkey MSC (13.63±1.54%) and HS-5 cells (16.02±2.58%) (Figure 3, middle panels) . The percentage of cells expressing AT 2 -receptors was also greater (p<0.05) than isotype control in the monkey MSC (64.43±4.11%) and in HS-5 cells (43.69±7.35%) (Figure 3 , lower panels).
Ang II-stimulated arachidonic acid release from monkey and human HS-5 marrow stromal cells
Results of Ang II-stimulation of monkey MSC are illustrated in Figure 4A . Release of 3 H-AA from monkey MSC was stimulated by Ang II (147 ± 4% of control, p<0.05) and PMA (176 ± 7% of control, p<0.05). Ang II-stimulated 3 H-AA release was abolished by the non-selective competitive Ang II receptor antagonist, Sar 1 -Thr 8 -Ang II, (91.2 ± 12% of control, p<0.05) (data not shown), and was reduced (p<0.05) to levels not different from control by either losartan (110 ± 4% of control), or PD 123319 (108 ± 5% of control). The combination of losartan and PD 123319 had no additional effect on Ang II-stimulated 3 H-AA release (108 ± 4% of control, p<0.05). Similar to findings in monkey MSC, 3 H-AA release from HS-5 cells was increased by Ang II (124 ± 3% of control, p<0.05) and PMA (141 ± 5% of control, p<0.05) ( Figure  4B ). While either losartan or PD 123319 reduced (p<0.05) Ang II-stimulated 3 H-AA release (109 ± 3% of control and 112 ± 5% of control, respectively) from HS-5 cells as in monkey MSC, AA release in both cases remained significantly greater than control. The combination of losartan and PD 123319 further reduced (p<0.05) Ang II-stimulated 3 H-AA release (101 ± 4% of control) to levels not different from control. In the absence of Ang II, 3 H-AA release from monkey and HS-5 MSC was unaffected by losartan (103 ± 2% and 98 ± 4% of control, respectively), PD 123319 (100 ± 2% and 97 ± 7% of control, respectively) or the combination (93 ± 6% and 96 ± 4% of control, respectively).
MCSF secretion from human HS-5 marrow stromal cells stimulated with Ang II
The concentration of secreted MCSF was measured in the culture medium following treatment of human HS-5 MSC for 24 hours with Ang II or PMA. Ang II had no effect on MCSF secretion, whereas PMA, which stimulated MCSF production in human MSC, 39 increased (p<0.05) MCSF concentration in culture medium from HS-5 cells by approximately 2-fold compared to control ( Figure  5 ). The Ang II receptor antagonists, losartan and PD 123319, had no effect on MCSF secretion in response to Ang II. 
Discussion
The major findings of this study were that Ang II stimulated the release of AA from MSC of monkey bone marrow origin and from the human HS-5 stromal cell line, but had no effect on HS-5 cell secretion of MCSF. The demonstration of AT 1 -and AT 2 -receptor protein in monkey and human MSC is in accordance with the co-expression of both receptors in other adult mammalian tissues. The levels of immunodetectable AT 1 -and AT 2 -receptor fluorescence were similar to those reported in human monocytes 40 and Lewis rat MSC. 17 Both AT 1 -and AT 2 -receptors were involved in the increase in AA release from MSC, since the receptor antagonists losartan and PD 123319 individually suppressed the stimulatory actions of Ang II.
These results correspond to studies in cardiomyocytes 24 and neuronal cells, 25 in which both AT 1and AT 2 -receptors mediated the release of AA by Ang II. The levels of Ang II-stimulated AA release from MSC were similar to those from rabbit aortic vascular smooth muscle cells 23 which express AT 1and AT 2 -receptors and in which both losartan-and PD 123319-sensitive AA release was demonstrated. We observed an additive effect of the combination of losartan and PD 123319 only in HS-5 cells, which may be accounted for by the relative homogeneity of the HS-5 cell line. Primary cultures obtained from either human or monkey bone marrow contain a greater variety of cell phenotypes 28;30 than HS-5 cells and therefore potentially a more diverse and complicated response to Ang II stimulation.
Results of analysis of AT 1 -receptor mRNA paralleled protein expression in monkey and human MSC determined by single-colour flow cytometry. This is the first description of AT 1 -receptor mRNA in nonhuman primate MSC and is consistent with previous reports demonstrating AT 1 -receptor mRNA in human HS-5 cells. 15 In contrast, AT 2 mRNA was not detected in either monkey or HS-5 cells, though protein expression was discernible in both cell types by flow cytometry. Our findings agreed with the previous demonstration that AT 2 mRNA was not detected in HS-5 cells. 15 The discrepancy in AT 2 -receptor mRNA and protein detection may be attributed to low expression or instability of AT 2 -receptor mRNA in MSC, thus below the detection limit of the RT-PCR method employed. Difficulties detecting AT 2 -receptor mRNA were reported in other tissues and cultured cell types. [41] [42] [43] It is evident from many cell culture studies that AT 2 -receptor expression, stability and detection are modified by a number of factors, including culture conditions. 44 However, we previously showed that cultured rat MSC not only had similar levels of immunodetectable AT 1 -and AT 2receptors as detected in monkey and human MSC, but also both AT 1 -and AT 2 -receptor mRNA. 17 The effect of PD 123319 on Ang II-associated AA release by MSC deserves careful interpretation, since previous studies from this and other laboratories raised questions concerning the specificity of PD 123319 as a selective AT 2 -receptor antagonist. 45, 46 We showed the existence of other forms of biologically active angiotensins 45 which may bind PD 123319. Our observation that Sar 1 -Thr 8 -Ang II mimics the individual effects of losartan and PD 123319 on MSC indicates that the effects of Ang II on AA release were mediated by an Ang II receptor mechanism, but this finding does not completely resolve the question of whether the responses elicited by PD 123319 were caused by blockade of AT 2 -receptors. While further studies will be needed to identify the signalling mechanism that mediates the effects of PD 123319, the consistent effects of AT 1 -receptor blockade in two separate cell systems underscore a critical modulatory role of Ang II in regulation of AA-release and its effects on the regulatory pathways of both typical and atypical haematopoiesis.
The production of MCSF by HS-5, 30 as well as by primary human MSC cultures, 39, 47 indicate that these cells may regulate haematopoiesis in the marrow microenvironment through modulation of MCSF secretion. Although Ang II was recently linked to circulating MCSF 26, 27 and the concentration of MCSF we measured in culture medium from HS-5 cells was similar to that reported by others, 30 we found no effect of Ang II-stimulation on the secretion of MCSF by human HS-5 MSC, suggesting that the constitutive secretion of MCSF from MSC is not responsive to Ang II stimulation.
Upon its release, AA can enter multiple pathways within the bone marrow microenvironment. Metabolism of AA results in eicosanoids and other metabolites known to be active in the regulation of haematopoiesis. In addition, free AA acts as a signalling molecule to influence proliferation or apoptosis of hematopoietic precursors. 48, 49 Given that AA and its metabolites represent a haematopoietic control mechanism, our studies provide the basis for further understanding of the role of Ang II in the regulation of both normal and dysfunctional haematopoiesis. 
